ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Japan’s Eisai Trims Headcount In U.S.

by Lisa M. Jarvis
April 20, 2015 | APPEARED IN VOLUME 93, ISSUE 16

The U.S. subsidiary of the Japanese drugmaker Eisai is cutting 25% of its workforce, which spans R&D, manufacturing, sales, and administrative functions. According to a notice filed with New Jersey’s Department of Labor & Workforce Development, 153 of the more than 200 lost jobs will come from its Woodcliff Lake, N.J., headquarters. The overhaul, which does not include the closure of any sites, is expected to be complete by May 1. Eisai has struggled with lackluster sales for the obesity drug Belviq, which it comarkets with Arena Pharmaceuticals. Eisai’s cuts come just weeks after Vivus Pharmaceuticals, which sells a competing obesity drug, laid off one-third of its sales force.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment